Application of an inducible system to engineer unmarked conditional mutants of essential genes of Pseudomonas aeruginosa

Journal of Microbiological Methods

Volumn 82, Issue 3, 2010, Pages 205-213

  Morita, Yuji ^a   Narita, Shin Ichiro ^b   Tomida, Junko ^a   Tokuda, Hajime ^b   Kawamura, Yoshiaki ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Essential genes; Pseudomonas aeruginosa; Unmarked gene disruption

Indexed keywords

BACTERIAL PROTEIN; BETA GALACTOSIDASE; ISOPROPYL THIOGALACTOSIDE; PROTEIN DEF; PROTEIN LOLCDE; PROTEIN LPXC; RHO FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATION; CONTROLLED STUDY; DNA SEQUENCE; ESSENTIAL GENE; EXPRESSION VECTOR; GENE DISRUPTION; GENE EXPRESSION; GENE TARGETING; GROWTH INHIBITION; GROWTH RATE; MUTATIONAL ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VALIDATION PROCESS;

PSEUDOMONAS AERUGINOSA;

EID: 77955658187     PISSN: 01677012     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mimet.2010.06.001     Document Type: Article

References (61)

1. Adams J.M. On the release of the formyl group from nascent protein. J. Mol. Biol. 1968, 33:571-589.
2. Alekshun M.N., Levy S.B. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007, 128:1037-1050.
3. Balasubramanian D., Mathee K. Comparative transcriptome analyses of Pseudomonas aeruginosa. Hum. Genomics 2009, 3:349-361.
4. Becher A., Schweizer H.P. Integration-proficient Pseudomonas aeruginosa vectors for isolation of single-copy chromosomal lacZ and lux gene fusions. Biotechniques 2000, 29(948-50):952.
5. Boneca I.G., Ecobichon C., Chaput C., Mathieu A., Guadagnini S., Prevost M.C., et al. Development of inducible systems to engineer conditional mutants of essential genes of Helicobacter pylori. Appl. Environ. Microbiol. 2008, 74:2095-2102.
6. Brencic A., McFarland K.A., McManus H.R., Castang S., Mogno I., Dove S.L., et al. The GacS/GacA signal transduction system of Pseudomonas aeruginosa acts exclusively through its control over the transcription of the RsmY and RsmZ regulatory small RNAs. Mol. Microbiol. 2009, 73:434-445.
7. Bubunenko M., Baker T., Court D.L. Essentiality of ribosomal and transcription antitermination proteins analyzed by systematic gene replacement in Escherichia coli. J. Bacteriol. 2007, 189:2844-2853.
8. Cardinale C.J., Washburn R.S., Tadigotla V.R., Brown L.M., Gottesman M.E., Nudler E. Termination factor Rho and its cofactors NusA and NusG silence foreign DNA in Escherichia coli. Science 2008, 320:35-38.
9. Caughlan R.E., Sriram S., Daigle D.M., Woods A.L., Buco J., Peterson R.L., et al. Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression. Antimicrob. Agents Chemother. 2009, 53:5015-5021.
10. Choi K.H., Schweizer H.P. mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa. Nat. Protoc. 2006, 1:153-161.
11. Choi K., Trunck L.A., Kumar A., Mima T., Karkhoff-Schweizer R.R., Schweizer H.P. Genetic tools for Pseudomonas. Pseudomonas Genomics and Molecular Biology 2008, 65-86. Caister Academic Press, Norfolk, UK. P. Cornelis (Ed.).
12. Engebrecht J., Brent R., Kaderbhai M.A. Minipreps of plasmid DNA. Current Protocols in Molecular Biology 1999, 1.6.1-10. John Wiley & Sons, Inc, New York, NY, USA. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl (Eds.).
13. Fischbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Science 2009, 325:1089-1093.
14. Fritsche T.R., Sader H.S., Cleeland R., Jones R.N. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. 2005, 49:1468-1476.
15. Guilloteau J.P., Mathieu M., Giglione C., Blanc V., Dupuy A., Chevrier M., et al. The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J. Mol. Biol. 2002, 320:951-962.
16. Guzman L.M., Belin D., Carson M.J., Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J. Bacteriol. 1995, 177:4121-4130.
17. Herring C.D., Blattner F.R. Conditional lethal amber mutations in essential Escherichia coli genes. J. Bacteriol. 2004, 186:2673-2681.
18. Heilig J.S., Elbing K.L., Brent R. Plasmid DNA purification by PEG precipitation. Current Protocols in Molecular Biology 1999, 1.7.9-15. John Wiley & Sons, Inc, New York, NY, USA. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl (Eds.).
19. Hoang T.T., Karkhoff-Schweizer R.R., Kutchma A.J., Schweizer H.P. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 1998, 212:77-86.
20. Hoang T.T., Kutchma A.J., Becher A., Schweizer H.P. Integration-proficient plasmids for Pseudomonas aeruginosa: site-specific integration and use for engineering of reporter and expression strains. Plasmid 2000, 43:59-72.
21. Hupert-Kocurek K., Sage J.M., Makowska-Grzyska M., Kaguni J.M. Genetic method to analyze essential genes of Escherichia coli. Appl. Environ. Microbiol. 2007, 73:7075-7082.
22. Hyland S.A., Eveland S.S., Anderson M.S. Cloning, expression, and purification of UDP-3-O-acyl-GlcNAc deacetylase from Pseudomonas aeruginosa: a metalloamidase of the lipid A biosynthesis pathway. J. Bacteriol. 1997, 179:2029-2037.
23. Imperi F., Ciccosanti F., Perdomo A.B., Tiburzi F., Mancone C., Alonzi T., et al. Analysis of the periplasmic proteome of Pseudomonas aeruginosa, a metabolically versatile opportunistic pathogen. Proteomics 2009, 9:901-915.
24. Inoue A., Murata Y., Takahashi H., Tsuji N., Fujisaki S., Kato J. Involvement of an essential gene, mviN, in murein synthesis in Escherichia coli. J. Bacteriol. 2008, 190:7298-7301.
25. Ito H., Ura A., Oyamada Y., Yoshida H., Yamagishi J., Narita S., et al. A new screening method to identify inhibitors of the Lol (localization of lipoproteins) system, a novel antibacterial target. Microbiol. Immunol. 2007, 51:63-70.
26. Jacobs M.A., Alwood A., Thaipisuttikul I., Spencer D., Haugen E., Ernst S., Will O., Kaul R., Raymond C., Levy R., Chun-Rong L., Guenthner D., Bovee D., Olson M.V., Manoil C. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14339-14344.
27. Jin Y., Watt R.M., Danchin A., Huang J.D. Use of a riboswitch-controlled conditional hypomorphic mutation to uncover a role for the essential csrA gene in bacterial autoaggregation. J. Biol. Chem. 2009, 284:8738-8745.
28. Lee S., Hinz A., Bauerle E., Angermeyer A., Juhaszova K., Kaneko Y., et al. Targeting a bacterial stress response to enhance antibiotic action. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14570-14575.
29. Leeds J.A., Dean C.R. Peptide deformylase as an antibacterial target: a critical assessment. Curr. Opin. Pharmacol. 2006, 6:445-452.
30. Lister P.D., Wolter D.J., Hanson N.D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 2009, 22:82-610.
31. Masaoka Y., Ueno Y., Morita Y., Kuroda T., Mizushima T., Tsuchiya T. A two-component multidrug efflux pump, EbrAB, in Bacillus subtilis. J. Bacteriol. 2000, 182:2307-2310.
32. Mazel D., Pochet S., Marliere P. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J. 1994, 13:914-923.
33. Meinnel T., Blanquet S. Evidence that peptide deformylase and methionyl-tRNA(fMet) formyltransferase are encoded within the same operon in Escherichia coli. J. Bacteriol. 1993, 175:7737-7740.
34. Mdluli K.E., Witte P.R., Kline T., Barb A.W., Erwin A.L., Mansfield B.E., et al. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50:178-184.
35. Miller J.H. Procedures for working with lac. A Short Course in Bacterial Genetics 1992, 71-74. Cold Spring Harbor Laboratory Press, Plainview, N. Y., U. S. A.
36. Montanari S., Oliver A., Salerno P., Mena A., Bertoni G., Tummler B., et al. Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 2007, 153:1445-1454.
37. Morita Y., Kodama K., Shiota S., Mine T., Kataoka A., Mizushima T., et al. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob. Agents Chemother. 1998, 42:778-782.
38. Morita Y., Kimura N., Mima T., Mizushima T., Tsuchiya T. Roles of MexXY- and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas aeruginosa PAO1. J. Gen. Appl. Microbiol. 2001, 47:27-32.
39. Morita Y., Komori Y., Mima T., Kuroda T., Mizushima T., Tsuchiya T. Construction of a series of mutants lacking all of the four major mex operons for multidrug efflux pumps or possessing each one of the operons from Pseudomonas aeruginosa PAO1: MexCD-OprJ is an inducible pump. FEMS Microbiol. Lett. 2001, 202:139-143.
40. Morita Y., Sobel M.L., Poole K. Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product. J. Bacteriol. 2006, 188:847-855.
41. Morita Y., Gilmour C., Metcalf D., Poole K. Translational control of the antibiotic inducibility of the PA5471 gene required for mexXY multidrug efflux gene expression in Pseudomonas aeruginosa. J Bacteriol. 2009, 191:4966-4975.
42. Nakashima N., Tamura T., Good L. Paired termini stabilize antisense RNAs and enhance conditional gene silencing in Escherichia coli. Nucleic Acids Res. 2006, 34:e138.
43. Narita S., Tokuda H. Amino acids at positions 3 and 4 determine the membrane specificity of Pseudomonas aeruginosa lipoproteins. J. Biol. Chem. 2007, 282:13372-13378.
44. Narita S., Tanaka K., Matsuyama S., Tokuda H. Disruption of lolCDE, encoding an ATP-binding cassette transporter, is lethal for Escherichia coli and prevents release of lipoproteins from the inner membrane. J. Bacteriol. 2002, 184:1417-1422.
45. Newton D.T., Creuzenet C., Mangroo D. Formylation is not essential for initiation of protein synthesis in all eubacteria. J. Biol. Chem. 1999, 274:22143-22146.
46. Nikaido H. Multidrug resistance in bacteria. Annu. Rev. Biochem. 2009, 78:119-146.
47. Oliver A., Levin B.R., Juan C., Baquero F., Blazquez J. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 2004, 48:4226-4233.
48. Qiu D., Damron F.H., Mima T., Schweizer H.P., Yu H.D. PBAD-based shuttle vectors for functional analysis of toxic and highly regulated genes in Pseudomonas and Burkholderia spp. and other bacteria. Appl. Environ. Microbiol. 2008, 74:7422-7426.
49. Peters J.M., Mooney R.A., Kuan P.F., Rowland J.L., Keles S., Landick R. Rho directs widespread termination of intragenic and stable RNA transcription. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5406-5411.
50. Schwartz A., Rabhi M., Jacquinot F., Margeat E., Rahmouni A.R., Boudvillain M. A stepwise 2'-hydroxyl activation mechanism for the bacterial transcription termination factor Rho helicase. Nat. Struct. Mol. Biol. 2009, 16:309-316.
51. Sekiguchi J., Asagi T., Miyoshi-Akiyama T., Kasai A., Mizuguchi Y., Araake M., et al. Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan. J. Clin. Microbiol. 2007, 45:79-89.
52. Steiner-Mosonyi M., Creuzenet C., Keates R.A., Strub B.R., Mangroo D. The Pseudomonas aeruginosa initiation factor IF-2 is responsible for formylation-independent protein initiation in P. aeruginosa. J. Biol. Chem. 2004, 279:52262-52269.
53. Stover C.K., Pham X.Q., Erwin A.L., Mizoguchi S.D., Warrener P., Hickey M.J., et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000, 406:959-964.
54. Strateva T., Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J. Med. Microbiol. 2009, 58:1133-1148.
55. Suh S.J., Silo-Suh L.A., Ohman D.E. Development of tools for the genetic manipulation of Pseudomonas aeruginosa. J. Microbiol. Methods 2004, 58:203-212.
56. Syn C.K., Swarup S. A scalable protocol for the isolation of large-sized genomic DNA within an hour from several bacteria. Anal. Biochem. 2000, 278:86-90.
57. Tanaka S.Y., Narita S., Tokuda H. Characterization of the Pseudomonas aeruginosa Lol system as a lipoprotein sorting mechanism. J. Biol. Chem. 2007, 282:13379-13384.
58. Vaara M. Lipid A: target for antibacterial drugs. Science 1996, 274:939-940.
59. Vettoretti L., Floret N., Hocquet D., Dehecq B., Plesiat P., Talon D., et al. Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:1217-1222.
60. Washburn R.S., Marra A., Bryant A.P., Rosenberg M., Gentry D.R. rho is not essential for viability or virulence in Staphylococcus aureus. Antimicrob. Agents Chemother. 2001, 45:1099-1103.
61. Wood L.F., Ohman D.E. Use of cell wall stress to characterize sigma 22 (AlgT/U) activation by regulated proteolysis and its regulon in Pseudomonas aeruginosa. Mol. Microbiol. 2009, 72:83-201.